KEI Industries Limited (BOM:517569)

Intra-Cellular Therapies Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	-	10,517	6,661	4,799	3,590	2,202
Cash & Short-Term Investments	10,517	10,517	6,661	4,799	3,590	2,202
Cash Growth	50.17%	57.90%	38.80%	33.67%	63.07%	84.20%
Accounts Receivable	-	18,103	15,326	14,006	14,169	13,710
Other Receivables	-	1,324	492.69	390.12	506.21	511.66
Receivables	-	19,445	15,840	14,417	14,688	14,231
Inventory	-	17,303	13,427	11,023	10,794	7,628
Prepaid Expenses	-	77.17	49.05	65.37	54.04	24.15
Other Current Assets	-	9,003	1,000	1,310	484.62	316.61
Total Current Assets	-	56,346	36,977	31,613	29,611	24,401
Property, Plant & Equipment	-	13,775	8,897	5,802	5,453	5,425
Long-Term Investments	-	17.18	15.87	12.7	20.16	12.84
Other Intangible Assets	-	10.55	15.37	16.87	20.73	17.87
Other Long-Term Assets	-	2,189	653.78	253.25	161.5	226.33
Total Assets	-	72,346	46,565	37,702	35,271	30,085
Accounts Payable	-	7,792	10,079	7,482	7,626	7,415
Accrued Expenses	-	1,138	1,025	627.04	472.99	418.2
Short-Term Debt	-	1,783	1,342	1,353	3,112	2,536
Current Portion of Long-Term Debt	-	-	-	-	201.89	195.8
Current Portion of Leases	-	80.56	61.58	46.57	33.42	42.36
Current Income Taxes Payable	-	16.82	3.78	54.57	146.57	80.6
Current Unearned Revenue	-	1,457	1,499	1,437	1,610	658.76
Other Current Liabilities	-	1,213	302.71	176.19	123.99	74.99
Total Current Liabilities	-	13,480	14,313	11,176	13,327	11,422
Long-Term Debt	-	-	-	-	-	312.99
Long-Term Leases	-	308.27	258.41	219.15	206.72	238.74
Long-Term Unearned Revenue	-	192.23	64.18	-	-	-
Long-Term Deferred Tax Liabilities	-	303.88	273.19	266.42	294.42	280.73
Other Long-Term Liabilities	-	204.01	172.73	148.79	87.72	91.23
Total Liabilities	-	14,489	15,082	11,810	13,915	12,345
Common Stock	-	191.11	180.48	180.38	180.21	179.71
Additional Paid-In Capital	-	26,032	6,201	6,127	6,087	5,974
Retained Earnings	-	31,524	24,978	19,508	15,008	11,467
Comprehensive Income & Other	-	110.88	123.13	76.24	79.98	119.4
Total Common Equity	57,858	57,858	31,483	25,892	21,355	17,740
Minority Interest	-	-	-	-0.18	-0.14	-0.08
Shareholders' Equity	57,858	57,858	31,483	25,892	21,355	17,740
Total Liabilities & Equity	-	72,346	46,565	37,702	35,271	30,085
Total Debt	2,172	2,172	1,662	1,618	3,554	3,326
Net Cash (Debt)	8,345	8,345	4,998	3,181	36.4	-1,124
Net Cash Growth	56.24%	66.96%	57.15%	8638.16%	-	-
Net Cash Per Share	89.27	90.54	55.30	35.23	0.40	-12.41
Filing Date Shares Outstanding	95.53	95.55	90.24	90.19	90.11	89.86
Total Common Shares Outstanding	95.53	95.55	90.24	90.19	90.11	89.86
Working Capital	-	42,866	22,664	20,438	16,284	12,979
Book Value Per Share	605.50	605.50	348.87	287.07	237.00	197.42
Tangible Book Value	57,847	57,847	31,467	25,875	21,335	17,722
Tangible Book Value Per Share	605.39	605.39	348.70	286.89	236.77	197.23
Land	-	306.09	301.17	256.5	190.63	96.98
Buildings	-	2,663	2,150	1,852	1,707	1,626
Machinery	-	8,371	6,195	5,489	5,159	4,840
Construction In Progress	-	3,855	1,209	145.59	165.06	71.33
Order Backlog	-	6,030	-	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.